Cogent Biosciences Inc. (NASDAQ: COGT) announced results from its PEAK Phase 3 trial showing bezuclastinib combined with sunitinib demonstrated superior ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA